Linked Life Data

17003255

Source:http://linkedlifedata.com/resource/pubmed/id/17003255

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2006-9-27
pubmed:abstractText
Cancer chemotherapy-related symptoms such as fatigue, malaise, loss of interest in social activities, difficulty concentrating, and changes in sleep patterns can lead to treatment delays, dose reductions, or termination and have a profound effect on the physical, psychosocial, and economic aspects of quality of life. Clinicians have long suspected that these symptoms are similar to those associated with "sickness behavior," which is triggered by the production of the inflammatory cytokines IL-1beta, TNF-alpha, and IL-6 by macrophages and other cells of the innate immune system in response to immune challenge. The p38 mitogen-activated protein kinase (p38 MAPK) plays a central role in the production of these cytokines and consequently the induction of sickness behavior. Several cancer chemotherapy drugs have been shown to activate p38 MAPK, but whether these drugs can also induce the production of inflammatory cytokines to cause sickness behavior is unknown. The aim of this study was to determine whether the cancer chemotherapy drug etoposide (VP-16), which is known to activate p38 MAPK, could induce inflammatory cytokine production by murine macrophages and sickness-like behaviors when injected into mice. VP-16 activated p38 MAPK and induced IL-6 production in murine macrophages in a p38 MAPK- dependent manner. VP-16 administration rapidly increased serum levels of IL-6 in healthy mice and induced sickness-like behaviors as evidenced by a decrease in food intake, body weight, hemoglobin level, and voluntary wheel-running activity. These findings support the idea that the induction of IL-1beta, TNF-alpha, and IL-6 by cancer chemotherapy drugs underlies the fatigue and associated symptoms experienced by people undergoing cancer chemotherapy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1099-8004
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
157-69
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:17003255-Analysis of Variance, pubmed-meshheading:17003255-Animals, pubmed-meshheading:17003255-Anorexia, pubmed-meshheading:17003255-Antineoplastic Agents, Phytogenic, pubmed-meshheading:17003255-Cachexia, pubmed-meshheading:17003255-Disease Models, Animal, pubmed-meshheading:17003255-Drug Evaluation, Preclinical, pubmed-meshheading:17003255-Drug Monitoring, pubmed-meshheading:17003255-Etoposide, pubmed-meshheading:17003255-Fatigue, pubmed-meshheading:17003255-Female, pubmed-meshheading:17003255-Interferon-beta, pubmed-meshheading:17003255-Interleukin-6, pubmed-meshheading:17003255-Macrophages, pubmed-meshheading:17003255-Mice, pubmed-meshheading:17003255-Mice, Inbred C57BL, pubmed-meshheading:17003255-Quality of Life, pubmed-meshheading:17003255-Sick Role, pubmed-meshheading:17003255-Sleep Disorders, pubmed-meshheading:17003255-Statistics, Nonparametric, pubmed-meshheading:17003255-Tumor Necrosis Factor-alpha, pubmed-meshheading:17003255-p38 Mitogen-Activated Protein Kinases
pubmed:year
2006
pubmed:articleTitle
The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms.
pubmed:affiliation
Oregon Health & Science University School of Nursing, 3455 SW US Veterans Hospital Road, Portland, OR 97239, USA. woodl@ohsu.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural